Last reviewed · How we verify
Cigarette
Cigarette is a Small molecule drug developed by M.D. Anderson Cancer Center. It is currently in Phase 2 development. Also known as: Participant will smoke their usual brand of cigarette.
Cigarettes are thin cylinders of smoking tobacco rolled in thin paper for smoking, typically ignited at one end and inhaled through the opposite end. Cigarette smoking is the most common method of tobacco consumption.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Cigarette |
|---|---|
| Also known as | Participant will smoke their usual brand of cigarette |
| Sponsor | M.D. Anderson Cancer Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- Using Smartwatches to Monitor Smoking in Real-life Situations
- Cognitive Task Development and Implementation for Functional MRI Studies
- Pharmacokinetics and Pharmacodynamics of Nicotine With Use of Standardized Research Electronic Cigarette (SREC) (NA)
- Reducing Tobacco Smoking: a Transcranial Direct Current Stimulation (TDCS) Telehealth Study (NA)
- Effects of Tobacco Abuse Liability-dependent Taxes in the ETM (NA)
- Effect of Nicotine Gingival Fibroblast Intoxication on the Response of Periodontal Treatment (NA)
- Multimodal Neuroimaging Genetic Biomarkers of Nicotine AddictionSeverity
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cigarette CI brief — competitive landscape report
- Cigarette updates RSS · CI watch RSS
- M.D. Anderson Cancer Center portfolio CI
Frequently asked questions about Cigarette
What is Cigarette?
Who makes Cigarette?
Is Cigarette also known as anything else?
What development phase is Cigarette in?
Related
- Manufacturer: M.D. Anderson Cancer Center — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Participant will smoke their usual brand of cigarette
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing